Study S000968

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05793450
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 20
Start: 2023-05-05
Primary completion: 2023-09-18
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Renal Impairment
Interventions: DRUG:IBI362
Results posted: FALSE

Registered primary outcomes

Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362 [Predose through 1344 hours postdose]
PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362 [Predose through 1344 hours postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.